Semaglutide vs Tirzepatide Miami —
which GLP-1 is right for you?
Both are FDA-approved GLP-1 weight loss injections available at Miami Injections — but they work differently, cost differently, and produce different results. Here's everything you need to know to make the right choice.
Semaglutide vs Tirzepatide: Head-to-Head in Miami
Both are available at Miami Injections with full physician supervision. Here's the honest clinical comparison.
Semaglutide
Ozempic® / Wegovy® · GLP-1 agonist
Best for:
Patients with cardiovascular risk, those who want the most studied GLP-1, or those starting their weight loss journey at a lower price point.
Tirzepatide
Mounjaro® / Zepbound® · Dual GIP+GLP-1
Best for:
Patients seeking maximum weight loss, those with insulin resistance or Type 2 diabetes, or patients who have plateaued on Semaglutide.
| Category | Semaglutide | Tirzepatide | Advantage |
|---|---|---|---|
| Mechanism | GLP-1 receptor agonist (single) | Dual GIP + GLP-1 agonist | Tirzepatide |
| Average weight loss | 14.9% (STEP-1 trial) | 20.9% (SURMOUNT-1 trial) | Tirzepatide |
| Maximum dose | 2.4mg/week (Wegovy) | 15mg/week (Mounjaro/Zepbound) | Tirzepatide |
| Cardiovascular data | 20% reduction in CV events (SELECT) | Ongoing (SURMOUNT-MMO) | Semaglutide |
| Years on market | 7+ years (Ozempic since 2017) | 3 years (Mounjaro since 2022) | Semaglutide |
| Starting price (Miami) | $34/dose ($136/mo) | $68/dose ($272/mo) | Semaglutide |
| Brand name equivalent | Ozempic® / Wegovy® | Mounjaro® / Zepbound® | Tie |
| GI side effects | Moderate (nausea, constipation) | Similar, often slightly less severe | Tirzepatide |
| Insulin resistance improvement | Significant | Superior (dual GIP pathway) | Tirzepatide |
| Best for | Patients with CV risk, proven tolerance, budget-conscious | Patients seeking maximum weight loss, insulin resistance | Tie |
How Miami patients choose between Semaglutide and Tirzepatide
Choose Semaglutide if…
- You want the most clinically studied GLP-1 with 7+ years of real-world data
- You have established cardiovascular risk (SELECT trial shows 20% CV event reduction)
- You're starting your first GLP-1 program and want to begin at a lower cost
- Your insurance covers Ozempic or Wegovy (same molecule)
- You want to test GLP-1 tolerance before committing to a higher-dose protocol
- You prefer the $34/dose starting price over Tirzepatide at $68/dose
Choose Tirzepatide if…
- You want the maximum clinically proven weight loss (20.9% average at max dose)
- You have Type 2 diabetes or significant insulin resistance
- You've plateaued on Semaglutide and want to escalate to a stronger protocol
- You're aiming for 20%+ total body weight loss and are willing to invest more
- 1 in 3 patients in trials lost over 25% of body weight — this is your target range
- You prefer a medication with slightly lower nausea relative to its efficacy
Semaglutide vs Tirzepatide Miami — Common Questions
Tirzepatide produces greater average weight loss (20.9% vs 14.9%) due to its dual GLP-1 + GIP mechanism. However, Semaglutide has 7+ years of real-world safety data and proven cardiovascular protection (20% reduction in major CV events in the SELECT trial). For patients who prioritize maximum weight loss and have insulin resistance, Tirzepatide is often preferred. For patients with established cardiovascular risk or who prefer a more studied medication, Semaglutide is excellent. Our Miami physicians evaluate your specific health profile and recommend the right choice.
Yes — many Miami patients start on Semaglutide and upgrade to Tirzepatide after 3–6 months. The transition requires a new physician evaluation and typically a restart at a low Tirzepatide dose (2.5mg/week) to allow your body to adjust to the new mechanism. Miami Injections manages these transitions safely with monthly check-in appointments.
Yes. Tirzepatide starts at $68/dose ($272–$552/month) vs Semaglutide at $34/dose ($136–$240/month) at Miami Injections. However, given that Tirzepatide produces significantly greater weight loss on average, many patients find the cost-per-pound-lost is comparable or even favorable for Tirzepatide.
Both medications share similar GI side effects — nausea, constipation, and reduced appetite — most prominent during dose escalation. Tirzepatide patients generally report slightly less nausea than Semaglutide patients at equivalent efficacy doses, likely because the GIP component has independent anti-nausea properties. Both medications are significantly better tolerated with gradual dose escalation, which our Miami physicians manage carefully.
Both are excellent for Type 2 diabetes management. Semaglutide (Ozempic) has the longest real-world diabetes data and proven cardiovascular outcomes. Tirzepatide (Mounjaro) produces superior A1C reduction and weight loss — the FDA has approved it specifically for Type 2 diabetes. Both are physician-prescribed at Miami Injections after a thorough evaluation of your diabetes history and current medications.
The best way to decide is with a physician consultation at Miami Injections. We review your health history, current medications, weight loss goals, and budget — then recommend the optimal starting medication and dose. Most patients start on Semaglutide (lower cost, more established) and escalate to Tirzepatide if results plateau. Call (305) 490-2240 or complete the intake form to get started.
Not sure which one? Our physicians decide with you.
The best Semaglutide vs Tirzepatide decision is made with a real physician who reviews your health history. At Miami Injections, that consultation is free and takes 15 minutes.